In our latest blog, Abingdon Health USA’s President, Chris Yates, explains how to build a feasibility plan that does more than prove your assay works: one that gives investors the evidence they need to back your next round.

Feasibility is where a diagnostic stops being an idea and becomes a product with a measurable chance of success. It is also the stage investors scrutinise most closely when deciding whether to fund what comes next. A prototype that performs on the bench is a strong start, but on its own it rarely carries a seed or Series A raise.

In Three Pillars, One Foundation: Aligning IVD Development, Regulation & Fundraising from Day One, I explored with Jonny Sharp of Cerelo Advisory how design review gates, regulatory milestones and funding rounds map onto one another. Completed feasibility, backed by a defined regulatory pathway, is the milestone that typically underpins a seed raise to support your MedTech development journey. This blog looks at how to plan that feasibility phase so that, when it ends, you have both a working prototype and a fundable story.

What Investors Really Look for at Feasibility

Investors are not only backing your science. They are backing evidence that development risk is falling on a timeline they can believe. A well-built feasibility plan lets them answer four questions with confidence:

  • Does it work? Against success criteria that were agreed before the work began, not after.
  • Can it be made? At commercial scale, from a secure supply chain, at a cost of goods the market will accept.
  • Can it be approved? With a regulatory route that has been identified, scoped and costed.
  • Where does the money get us? To a milestone the next tier of investors will recognise and value.

Feasibility data that only answers the first question leaves the other three to be resolved during due diligence. That usually happens on your project runway (or your friend and family’s runway!), not the investor’s.

Five Building Blocks of an Investable Feasibility Plan

1. Define Success Before You Start

Every diagnostics feasibility program should begin with a clear product requirement specification: intended use, intended user, sample type, target sensitivity and specificity, time to result and a target cost of goods. As we set out in Lateral Flow Test Development: Key Process Milestones Explained, the output of feasibility is a working prototype that broadly meets these requirements, confirmed at a design review stage gate.

For MedTech investors, this turns feasibility from open-ended research into a go / no-go decision with defined criteria. It also gives them a benchmark against which every subsequent milestone can be measured.

2. Design for Manufacture from Day One

The reagents, membranes and components you select during feasibility shape everything that follows. Choosing antibodies available from more than one qualified supplier, or reagent preparation methods that suit industrial mixing equipment, can save significant time and cost later. Our blog on Technical Transfer Best Practices explains how these early decisions determine whether the move from bench to commercial manufacturing is smooth or expensive.

Record the details as you go: process parameters, which variables matter most to performance, and how problems were solved. This information makes later transfer easier and shows investors that scale-up has been considered, not deferred.

3. Scope Your Regulatory Pathway Early

You do not need a full regulatory submission strategy at feasibility, but you should know where you are heading. At a minimum, classify your device and identify the likely route to market, whether FDA 510(k), De Novo or PMA in the US, CE marking under IVDR in Europe, or UKCA in Great Britain. Outline what performance evaluation and clinical evidence that route will require. When considering which market to initially target, also think economics and regulatory ease. For example, the US is the largest healthcare market globally, representing 40% of global healthcare (with 4% of the global population). It is an early adopter of healthcare innovation, and the regulatory pathway is straightforward and the timelines clear.

As you approach Series A, a costed Regulatory Strategy Plan and, where relevant, an FDA pre-submission (Q-Sub) give investors real clarity on timelines and spend.

4. Build a Costed Roadmap Beyond Feasibility

Investors want to see the whole journey, not just the next step. My advice? Map each phase with indicative timings and costs:

  1. Feasibility: a working prototype that passes its design review gate.
  2. Optimisation: refined components and processes, plus a defined QC panel.
  3. Scale-up: a pilot batch, typically 1,000 to 5,000 devices on production equipment, leading to design freeze.
  4. Technical transfer: three independent batches of increasing size, confirming quality and a robust manufacturing process.
  5. Evidence and submission: clinical, stability and analytical studies using transfer batches, then regulatory submission.

Then line the roadmap up against your funding plan. Before each raise, ask: which design review gate and which regulatory milestone will we have reached when this capital runs out? If the answer is not a milestone the next investors will recognise, the plan needs to change.

5. Document Progressively

Feasibility does not need a full design history file, but it does need records that will stand up to due diligence. Keep protocols, raw data, design review minutes and the rationale behind key decisions. When formal design controls begin ahead of Series A, you will be building on a solid base rather than reconstructing history under time pressure. Formal design also requires the right ISO-certified CDMO partner, a key consideration at the outset.

Common Pitfalls, and Why Your Partner Matters

The team at Abingdon Health sees the same feasibility mistakes undermine otherwise promising fundraises:

  • Treating feasibility as pure science. Strong data, but no agreed specification, no view on manufacturability and no regulatory plan. The gaps surface at scale up or in due diligence and take months to fix.
  • Over-engineering too early. Spending seed capital on full design-control documentation and regulatory consultancy before the core assay concept is proven. Formality should grow as risk falls.
  • Optimistic timelines. Raising on an 18-month plan for a program that realistically needs 30 means returning to investors early, often on worse terms or failing to raise capital in the first instance if the plans aren’t credible.
  • Choosing on price alone. In The Real Cost of Choosing the Cheapest CDMO, we noted that a lower-cost provider can make sense for high-risk early feasibility. The risk comes when a narrowly scoped quote leads to change orders, data that is not fit for regulatory use, or a forced switch of partner before scale-up. Also having the work being performed by an ISO-certified CDMO de-risks a lack of credibility in the vigor of the development processes being followed.

This is why choosing a development partner is a fundraising decision as well as a technical one. An integrated CDMO that can take your product from feasibility through optimisation, technical transfer, regulatory submission and commercial manufacturing removes hand-offs that add risk and time. Just as importantly, an experienced partner can talk directly to your investors, helping them verify what they have been told and giving them confidence in the plan.

Turning Feasibility into Your Next Round

A feasibility plan built for investment proves more than technical viability. It shows that you know what success looks like, that your product can be manufactured and approved, and that each round of funding buys a milestone towards that matters. Plan development, regulation and fundraising together, and your feasibility results become the foundation of your next pitch.

Looking for Support?

Abingdon Health works with diagnostics founders and CEOs from feasibility through to commercial manufacturing and regularly supports customers’ conversations with current and prospective investors. As an integrated lateral flow CDMO and CRO with ISO 13485 and ISO 9001 certification, we combine assay development, technical transfer, regulatory services and analytical testing, with manufacturing in York, UK and Madison, Wisconsin, USA. Get in touch to discuss how we can help you build a feasibility plan that investors want to back.

Further Reading

Share this article